Proteomic Adaptations in the Spinal Cord of a Breast Cancer Model of Paclitaxel-Induced Peripheral Neuropathy
Journal of Proteome Research · 2026
DOI: 10.1021/acs.jproteome.6c00124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteome Research, 2026. Verfasst von Samantha P Schwarting und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Systems Biology, George Mason University, Manassas, Virginia20110, United States. Hauptthemen laut MEDLINE: Paclitaxel, Peripheral Nervous System Diseases, Spinal Cord, Proteome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health (NIH), 4-VA Collaborative Research Grant.
Abstract (Originalsprache)
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting side effect of taxane-based chemotherapy used in breast cancer treatment. Despite its prevalence, no FDA-approved therapies exist for CIPN prevention or treatment, highlighting the need for target prioritzation studies. Using label-free liquid chromatography–electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS), we examined the effects of four doses of paclitaxel (8 mg/kg) on the lumbar (L4–L6) spinal cord proteome in MMTV-PyMT-derived breast cancer bearing C57BL/6J mice. Breast cancer altered the expression of 551 proteins relative to naïve mice, while paclitaxel treatment in tumor-bearing mice altered 112 proteins relative to vehicle-treated cancer controls. Thirty-eight proteins were commonly affected by both conditions. Gene ontology enrichment and STRING protein–protein interaction analyses identified pathways linked to mitochondrial metabolism, ion transport, and neurotransmitter signaling. Pathway mapping further revealed convergent effects of breast cancer and paclitaxel on neuronal activation, neurotransmitter uptake, and mitochondrial dysfunction. Together, these findings define spinal cord proteomic alterations associated with acute paclitaxel-induced peripheral neuropathy and identify pain-relevant pathways for future mechanistic studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Systems Biology, George Mason University, Manassas, Virginia20110, United States.
- Center for Applied Proteomics and Molecular Medicine, Manassas, Virginia20110, United States.
- Department of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, Virginia23298, United States.
- Department Pathology, Massey Comprehensive Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia23298, United States.
ORCID-Profile: Virginia Espina, Yogesh Rakholia, M Imad Damaj, Nadine Kabbani
Förderung
- NCI NIH HHS
- National Institutes of Health (NIH)
- 4-VA Collaborative Research Grant
Zitieren
APA
Schwarting, S. P., Espina, V., Russo, P. S., Herz, S. M., Khan, A., Rakholia, Y., Makar, S., Bos, P. D., Damaj, M. I., & Kabbani, N. (2026). Proteomic Adaptations in the Spinal Cord of a Breast Cancer Model of Paclitaxel-Induced Peripheral Neuropathy. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.6c00124
Vancouver
Schwarting SP, Espina V, Russo PS, Herz SM, Khan A, Rakholia Y, et al. Proteomic Adaptations in the Spinal Cord of a Breast Cancer Model of Paclitaxel-Induced Peripheral Neuropathy. Journal of Proteome Research. 2026. doi:10.1021/acs.jproteome.6c00124
BibTeX
@article{Schwarting2026,
author = {Schwarting, Samantha P and Espina, Virginia and Russo, Paul S and Herz, Sara M and Khan, Abrar and Rakholia, Yogesh and Makar, Sandra and Bos, Paula D and Damaj, M Imad and Kabbani, Nadine},
title = {Proteomic Adaptations in the Spinal Cord of a Breast Cancer Model of Paclitaxel-Induced Peripheral Neuropathy},
journal = {Journal of Proteome Research},
year = {2026},
doi = {10.1021/acs.jproteome.6c00124}
}
EUVIMED